MREO (Mereo BioPharma Group) EBITDA Margin %: 0.00% (As of Mar. 2026)


MREO Mereo BioPharma Group PLC MREO
19 GF Score
Price $0.33
! 1 Warning Sign
View Full Analysis

What is Mereo BioPharma Group EBITDA Margin %?

Mereo BioPharma Group MREO +3.62% 19 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates MREO with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, Mereo BioPharma Group ranks worse than 91.8% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Mereo BioPharma Group's EBITDA for the three months ended in Mar. 2026 was $-6.39 Mil. Mereo BioPharma Group's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Mereo BioPharma Group's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Mereo BioPharma Group  (NAS:MREO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Mereo BioPharma Group EBITDA Margin % Related Terms

Mereo BioPharma Group EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Mereo BioPharma Group's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mereo BioPharma Group EBITDA Margin % Chart

Mereo BioPharma Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51.79 0.00 -260.56 0.00 -8,094.80

Mereo BioPharma Group Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -2,858.80 0.00 0.00 0.00

MREO vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Mereo BioPharma Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mereo BioPharma Group EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's EBITDA Margin % falls into.


MREO
19GF Score
Mereo BioPharma Group PLC MREO
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mereo BioPharma Group EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Mereo BioPharma Group's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-40.474/0.5
=-8,094.80 %

Mereo BioPharma Group's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-6.394/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Mereo BioPharma Group (MREO) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mereo BioPharma Group and its competitors. According to the industry distribution chart, Mereo BioPharma Group ranks #862 out of 939 companies in the Biotechnology industry, placing it in the top 91.8%.
Is Mereo BioPharma Group's EBITDA Margin % too high?
Mereo BioPharma Group's current EBITDA Margin % is 0.00%. Based on the distribution chart, Mereo BioPharma Group ranks #862 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mereo BioPharma Group has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Mereo BioPharma Group's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mereo BioPharma Group ranks #862 out of 939 companies for EBITDA Margin %. This places Mereo BioPharma Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Mereo BioPharma Group and its competitors. Mereo BioPharma Group's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mereo BioPharma Group stock overvalued right now?
Mereo BioPharma Group (MREO) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Mereo BioPharma Group's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Mereo BioPharma Group (MREO), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mereo BioPharma Group Business Description

Other Exchanges 0A9G:UKMAH0:Germany
Address One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
19GF Score

Get the complete analysis for MREO

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price